FY2025 · ended Dec 31, 2025 · Revenue $36.31M, +4.1% YoY · Filed Apr 3, 2026
Sunshine Biopharma Inc. (SBFM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $36.3 million and a net loss of $6.0 million. Free cash flow was -$5.5 million. As of Jun 30, 2026 it held $13.7 million in cash and investments and $678,338 in total debt.
Revenue (TTM)
$35.35M
-2.7% vs year-ago TTM
Net income (TTM)
$-5.83M
+7.5% vs year-ago TTM
Operating cash flow (TTM)
$-5.35M
+30.8% vs year-ago TTM
Free cash flow (TTM)
$-5.37M
EPS
$-7.32
+97.9% vs prior year
Dividend per share
None
Shares outstanding
4.91M
+81.2% vs prior year
Net cash
$13.07M
as of Jun 30, 2026
Operating margin
-16.6%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SBFM (Nasdaq), SBFMW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CO
- Headquarters
- Fort Lauderdale, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1402328
- Former names
- Sunshine Biopharma, Inc (until Oct 17, 2024); Mountain West Business Solutions, Inc (until Nov 2, 2009); mountain west business solutions,inc (until Oct 19, 2007); mountain state business solutions,inc (until May 25, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M |
| Diluted EPS | — | -$7.32 | -$351.36 | -$1.76 | — |
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
| Stockholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $211,662 |
| Cash and investments | $9.1M | $9.7M | $16.3M | $21.8M | $2.0M |
| Total debt | $812,422 | $952,480 | $657,705 | $765,258 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 9, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Other events
|
Sep 11, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 28, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
All 428 Sunshine Biopharma Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.